marked.bio

CD33 ADC · ADC

gemtuzumab ozogamicin

4 active trials across 2 of our biomarkers, targeting CD33. Not approved for any biomarker on marked.bio yet.

Also known as Mylotarg.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
FLT3 mutation (ITD/TKD) 3 5 Phase 3
NPM1 mutation 1 2 Phase 1

Trials

4 of 7 trials shown

  1. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

    Recruiting Phase 3 Children's Oncology Group Started 2020Primary completion 2029-06 NCT04293562

    Asparaginase Erwinia chrysanthemicytarabinedaunorubicinDexrazoxane Hydrochlorideetoposidegemtuzumab ozogamicingilteritinib FDA EUCPX-351methotrexatemitoxantroneTherapeutic Hydrocortisone

    …to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia

  2. A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

    Active, not recruiting Phase 2 Centre Antoine Lacassagne Started 2023Primary completion 2028-07 NCT05199051

    cytarabinegilteritinib FDA EUgemtuzumab ozogamicin

    Presence of a FLT3-ITD mutation (allelic ratio ≥0.05 at last evaluation)\* or a FLT3 TKD mutation

    FLT3 mutation (ITD/TKD)AML, Leukaemia (Acute Myeloid)

  3. Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

    Recruiting Phase 1/2 Technische Universität Dresden Started 2020Primary completion 2027-04 NCT04385290

    cytarabinedaunorubicinmidostaurin FDA EUgemtuzumab ozogamicin

    FLT3-ITD or

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia

  4. A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

    Recruiting Phase 1 M.D. Anderson Cancer Center Started 2025Primary completion 2028-12 NCT06448013

    venetoclaxgemtuzumab ozogamicinziftomenib FDA

    Presence of KMT2Ar, NUP98r, NPM1c, UBTF-ITD or other HOX pathway mutation.

    NPM1 mutationAcute Myeloid Leukemia